- Consumer Products
- Latest 77.20
- Currency US$
- Change -0.04
- Percent Change -0.052 %
- Volume 852,493
- Mon Mar 10, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Dec 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Mar 3||$-0.34||Apr 24||$-0.43|
12 months ended Mar 11, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.